Document Detail

A contemporary approach to thrombolytic therapy for pulmonary embolism.
MedLine Citation:
PMID:  10943588     Owner:  NLM     Status:  MEDLINE    
Successfully utilized contemporary pulmonary embolism thrombolysis reverses right heart failure rapidly and safely. This therapeutic approach may lower mortality from pulmonary embolism and reduce morbidity from chronic pulmonary hypertension. Unlike myocardial infarction thrombolysis, a 2-week 'time window' is available, during which treatment can be initiated. A high concentration of the thrombolytic agent is administered in a brief infusion lasting several hours. No special laboratory testing is needed. Currently, the only contemporary thrombolytic regimen for pulmonary embolism that is approved by the Food and Drug Administration is tissue plasminogen activator, in a dose of 100 mg/2 h. New thrombolytic agents under development for pulmonary embolism include reteplase, saruplase, and recombinant staphylokinase. Future clinical trials will require multicenter collaboration and will focus on relevant endpoints such as the reduction of mortality and recurrent venous thromboembolism.
S Z Goldhaber
Related Documents :
8575588 - Physical examination of the adult patient with respiratory diseases: inspection and pal...
1791208 - Pulmonary infarction, myocardial infarction, and acute disseminated intravascular coagu...
7306468 - Pleural mesothelioma presenting as apparent recurrent pulmonary embolism.
9699938 - Diagnostic accuracy of doppler-echocardiography in unselected patients with suspected p...
2670058 - Abdominal aortic aneurysms: a review of current problems.
14963678 - Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Vascular medicine (London, England)     Volume:  5     ISSN:  1358-863X     ISO Abbreviation:  Vasc Med     Publication Date:  2000  
Date Detail:
Created Date:  2000-11-13     Completed Date:  2000-11-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9610930     Medline TA:  Vasc Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  115-23     Citation Subset:  IM    
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Fibrinolytic Agents / therapeutic use*
Hemodynamics / drug effects,  physiology
Pulmonary Embolism / drug therapy*,  physiopathology
Thrombolytic Therapy*
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antisense and gene therapy to prevent restenosis.
Next Document:  Chromium, exercise, and body composition.